Autologous bone marrow stem cell transplantation treatment for 32 patients with Parkinson disease

QU Xinhui,XIE Xufang,ZHOU Chao,ZHANG Kunnan,WU Xiaomu

2013-01-01

Abstract:Objective To observe the clinical efficacy and security of the treatment of autologous bone marrow stem cell transplantation for patients with Parkinson disease. Methods 32 patients with Parkinson disease in Neurology Department of the People's Hospital of Jiangxi Province from January 2010 to July 2012 were selected. After bone marrow stem cell of the patients were mobilized, bone marrow stem cells(1.0-10.0) × 107/L were collected for transplantation therapy by intrathecal injection for two times, once a week. The efficacy was assessed by the index changes of unified Parkinson disease rating scale(UPDRS) score pre-transplant and after transplant and the adverse reactions of the patients were observed. Results There were 32 patients entered the final analysis, without shedding. The UPDRS scores of 1 and 3 months after transplantation were significantly lower than pre-transplant(all P < 0.05), especially motor function and activities of daily living were improved significantly(all P < 0.01). There was no significant difference between the UPDRS scores of 6 months after transplantation and the UPDRS scores of pre-transplant(P > 0.05). The improvement rates of clinical symptoms of 1, 3 and 6 months after transplantation were 71.9%, 78.1% and 31.3% respectively. There were 6 cases of low-grade fever, 2 cases of low cranial pressure pain the symptoms were cured completely after treatment. Conclusion The adverse reactions of autologous bone marrow stem cell transplantation are mild. In the short term, autologous bone marrow stem cell transplantation can improve the clinical symptoms of Parkinson disease and improve the life quality of patients, but they can not last.